Mentari Therapeutics, Inc. Common Stock

MTRI

시가총액 US$10.7억

소개: Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities focus on therapeutic candidates targeting PACAP and CGRP-related mechanisms for migraine prevention.